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RESEARCH ARTICLEElectrospun Nanofibrous Meshes Cultured With
Wharton’s Jelly Stem Cell: An Alternative for Cartilage
Regeneration, Without the Need of Growth FactorsMarta Alves da Silva, Albino Martins, Ana R. Costa-Pinto, Nelson Monteiro,
Susana Faria, Rui L. Reis, and Nuno M. Neves*Many efforts are being directed worldwide to the treatment of OA-focal lesions.
The majority of those efforts comprise either the refinement of surgical
techniques or combinations of biomaterials with various autologous cells.
Herein, we tested electrospun polycaprolactone (PCL) nanofibrous meshes for
cartilage tissue engineering. For that, articular chondrocytes (hACs) isolated
from human osteoarthritic joints and Wharton’s Jelly Stem Cells (hWJSCs) are
cultured on electrospun nanofiber meshes, without adding external growth
factors. We observed higher glycosaminoglycans production and higher over-
expression of cartilage-related genes from hWJSCs cultured with basal medium,
when compared to hACs isolated from osteoarthritic joints. Moreover, the
presence of sulfated proteoglycans and collagen type II is observed on both
types of cell cultures. We believe that this effect is due to either the electrospun
nanofibers topography or the intrinsic chondrogenic differentiation potential of
hWJSCs. Therefore, we propose the electrospun nanofibrous scaffolds in
combination with hWJSCs as a viable alternative to the commercial membranes
used in autologous chondrogenic regeneration approaches.1. Introduction
Articular cartilage pathological conditions still present great
demands in the ﬁeld of orthopaedic medicine. A wide variety of
those conditions involve loss of articular cartilage, for example
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cartilage may evolve to OA. One of the main
characteristics of OA lesions is an imbalance
in the joint cartilage that causes remodelling
of the subchondral bone and changes in the
composition of the synovial membrane.[2]
Microfracture has been widely used as a
one-step arthroscopic procedure, involving
debridment and exposure of the subchon-
dral bone, allowingbonemarrow toﬂow into
thesynovial space.[3]Themajordrawbacksof
microfracture are the poor biomechanical
properties of the repaired tissue, a partial
defect ﬁlling, and abnormal bone growth at
the lesion area.[4] Autologous transplanta-
tion approaches are focused in repairing the
articular cartilage by using implants that
carry autologous cells, isolated fromabiopsy
and pre-cultured in vitro. ACI (autologous
chondrocytes implantation) has become the
most applied clinical cell based therapy for
the repair of cartilage injuries over the past
decade. In this technique, expanded autolo-gous articular chondrocytes are implanted under a periosteal ﬂap
after surgical debridement of the lesion.[5] ACI has demonstrated
excellent short tomid-term repair although the evaluation of long-
termrepair remains somewhat controversial.[6] The techniquewas
further developed into the use of scaffolds as supports for cell
growth (e.g., MACI  Matrix induced articular chondrocytes
implantation),[7] where other sources of autologous cells including
mesenchymal stem cells (MSCs), periosteum-derived cells, and
synovial ﬁbroblasts[8] may be used. However, both ACI andMACI
involve two surgical interventions (one for removing healthy cells
from the donor site, and the other to implant the cells/matrix), as
well as several limitations concerning the patient mobility and
quality of life, namely donor site morbidity, long-term pain, and
reduced mobility. Moreover, the outcome of those approaches is
suboptimal, since the tissue formed consists frequently of
ﬁbrocartilage, which is not fully functional, nor long lasting.[9]
The most common tissue source of adult MSCs is the bone
marrow,[10,11] and these cells (BMSCs) have been used inseveral
Tissue Engineering (TE) applications, including for cartilage
repair.[10,12–15] Yet, issues such as the narrow number of available
MSCs in bone marrow,[16] and the likelihood of donor site
morbidity leads to the interest in identifying other MSCs
sources. Human umbilical cord Wharton’s jelly has been017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.biotechnology-journal.comreported as a prospective alternative tissue source,[17,18] since
human umbilical cord MSCs share many properties with
BMSCs, thus supporting their suitability for cell-based thera-
pies.[19] The source tissue fromwhere stem cells are isolated may
inﬂuence the chondrogenic effect of co-culturing chondrocytes
with those MSCs.[20] In the case of WJSCs, their ability for
osteogenic differentiation with the support of hierarchical
scaffolds has been reported by our group.[21] Moreover, their
ability to undergo chondrogenic differentiation in a trachea
tissue engineering approach has been recently reported.[22]
Some other works have been exploring the chondrogenic
potential of WJSCs with or without a 3D support,[23–25] but all of
them use exogenous growth factor supplementation for the
induction of the cartilage phenotype. However, the use of
bioactive factors has raised several limitations: their half-life is
too short to ensure in vivo efﬁcacy, a single administration is
usually not sufﬁcient to attain a adequate biological effect, the
quantities required are prohibitively expensive, and continuous
protein production increases the likelihood of undesired
outcomes.[26] Moreover, human MSCs isolated from fetal and
adult bone marrow have been reported to show distinct
differences in their sensitivity to speciﬁc growth factors.[27]
Therefore, one may inquire if these growth factors can indeed
trigger the coordinated sequence and level of signals required for
MSCs differentiation pathways, without the loss of crucial
genotypic and phenotypic functions. Employing a strategy that
avoids the use of growth factors, such as the one being reported
herein, will overcome the above mentioned limitations.
In this work we explore the prospective of electrospun PCL
nanoﬁber meshes (NFMs) as an alternative to the conventional
membranes supporting autologous transplantation
approaches, such as Hyalograft or AMIC1. These membranes
are mainly based on hyaluronic acid or collagen, respectively.
Electrospun NFMs used herein are produced using a synthetic
polymer (PCL) that was already approved by the regulatory
agencies for resorbable sutures and other implantable devices.
Furthermore, our meshes do not involve animal-derived
biomaterials such as collagen that usually pose concerns in
the consistency and variability, as well as on probability of
disease transmission. Electrospun PCL NFMs are intended to
act as a selective barrier for cells present in the synovial ﬂuid,
but enabling permeation by the synovial ﬂuid and soluble
molecules. Along with this advantage, the PCL membranes
present an architecture that recreates the ﬁbrillar structure of
the ECM.[28,29] It is described that the nanoscale topography of
materials can inﬂuence the fate of stem cells.[30] Thus, the
objective is to determine if the topography of the electrospun
NFMs is also able, per se, to induce in vitro chondrogenic
differentiation of human Wharton’s Jelly Stem Cells (hWJSCs).
We used human osteoarthritic articular chondrocytes (hACs)
isolated from knee sample of patients undergoing arthroplasty
surgeries, as clinically relevant controls.2. Experimental Section
2.1. Fabrication of Electrospun Meshes
NFMswere fabricated by the electrospinning process, as previously
described[31] and patent protected (WO 2014/016816). Brieﬂy, aBiotechnol. J. 2017, 1700073 1700073 (polymeric solution was prepared by dissolving PCL into an organic
solvent mixture of chloroform:DMF (70:30), at a concentration of
17wt-%. The polymeric solution was put into a syringe with a
coupled blunted metallic needle. The syringe was coupled to a
syringe pump (model KDS100, KD Scientiﬁc, Holliston, MA) in
order to control the ﬂow rate of the solution. A high-voltage power
supply (0–25kV) was applied to the needle to generate a constant
electric ﬁeld of 12 kV. The needle tip-to-collector distance and the
ﬂow rate were ﬁxed at 20 cm and 1.0mLh1, respectively. The
produced PCL nanoﬁbermeshes presented a thickness between 40
and60μm,70–80%ofporosity,determinedbynCT(datanotshown)
and an average pore size of 2.7μm. For more details on the PCL
nanoﬁber meshes, please refer to Guimar~aes et al.[32] After
collection, nanoﬁber meshes were cut into 1 cm2 squares.2.2. Human Articular Chondrocytes Isolation
Chondrocytes isolation was performed according to the method
previously reported by us.[33] Brieﬂy, cells were isolated from
human knees samples, namely from the medial and lateral
condyles. Samples were collected after obtaining informed
consent from the patients undergoing arthroplasties in Centro
Hospitalar do Alto Ave, Guimar~aes, Portugal. Cartilage pieces
were removed from the knee samples and went by sequential
enzymatic digestion for hACs isolation. After cells isolation, they
were plated and cultivated with expansion medium: Dulbecco’s
modiﬁed Eagle’s medium (Sigma, D5671), containing 10mM
Hepes buffer (Sigma, H0887), L-alanyl-L-glutamine (Sigma,
G8541), Non-Essential Aminoacids (Sigma, M7145), antibiotic/
antimitotic solution (Gibco, 15240062), 10% fetal bovine serum
(Gibco, 10270106), and 10 ngmL1 of basic Fibroblast Growth
Factor (bFGF) (PeproTech, 100-18B). Cells were expanded until
passage 4 and then used for seeding the NFMs.2.3. Human Wharton’s Jelly Stem Cells Isolation
Human umbilical cords were obtained after obtaining informed
consent from full-term caesarian sections donors, under the
scope of the cooperation agreement of the 3B́s Research Group
of the University of Minho and the Obstetrics Department of the
Hospital de S~ao Marcos, Braga, Portugal. Human WJSCs were
isolated according to the procedure previously described by
us.[33] Brieﬂy, cells were isolated from umbilical cords by
enzymatic digestion, plated and cultured using α-MEMmedium
(Gibco, 12000-063), supplemented with antibiotic/antimycotic
solution and 10% fetal bovine serum. Cells were expanded until
passage 4 and then seeded onto the NFMs.2.4. Cell Seeding Onto Electrospun PCL NFMs
A suspension of 200 000 hACs, or 200 000 hWJSCs, was used for
seeding the NFMs, in static culture conditions, at 37 C and 5%
CO2, during 24 h. The seeding density has been selected based
on our previous reports using PCL NFMs.[31,34,35] Basic medium
was used: Dulbecco’s modiﬁed Eagle’s Medium containing
10mM Hepes solution, L–alanyl–L–glutamine, Non-Essential© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim2 of 9)
www.advancedsciencenews.com www.biotechnology-journal.comAminoacids, antibiotic/antimicotic and 10% fetal bovine serum.
Afterwards, the constructs were transferred to new culture plates
containing differentiation medium, in the case of hACs, or α-
MEMmedium, in the case of hWJSCs. The hACs differentiation
medium is a modiﬁcation of the expansion medium: instead of
adding bFGF, the medium was supplemented with 1mgmL1
of L-ascorbic acid (Sigma, A8960) and 50mgmL1 of insulin
(Sigma, I5500). The α-MEM medium was prepared as described
above. The constructs were cultured during 28 days and the
culture medium was changed every 2–3 days.2.5. Cells Viability Assay
Three constructs were collected at every time point: 7, 14, 21,
and 28 days, and per each cell type, three per condition. A
solution of 10% alamar blue (AbD Serotec, BUF012B) in
differentiation medium (for hACs) or in α-MEM (for hWJSCs)
was added to each construct and incubated for 4 h. After
incubation, a 250mL aliquot was taken from each well and
placed in a 96 well plate, in triplicate for each sample. OD was
determined in a microplate reader (Bio-Tek, model Synergie
HT, USA), at 570 and 600 nm.2.6. Cells Proliferation Assay
The evaluation of the cells’ proliferation was performed using
the Quant-IT PicoGreen dsDNA Assay Kit (Invitrogen, P7589),
according to the manufacturer protocol. Triplicate samples were
collected at each time point, for each type of cells, and a standard
curve was established using known DNA concentrations
(0–1.5 μgmL1). Fluorescence of both the samples and of the
standard curve concentrations was read with an excitation of
485 nm and an emission of 528 nm, in a microplate reader (Bio-
Tek, model Synergie HT). The DNA concentrations of the
samples were interpolated directly from the standard curve.2.7. DMB Assay for GAGs Quantification
DMB assay was performed according to the method described
by Kaﬁenah and Sims.[36] Brieﬂy, three samples were collected
at every time point, and for each cell type, frozen overnight and
then digested. The digestion solution was prepared by adding
1mgmL1 of proteinase K (Sigma, P8044) diluted in 50mM
Tris–HCl, at pH of 7.6. Samples were incubated with 1mL of
the proteinase K solution overnight at 60 C. For each assay,
20 μL of samples and 250 μL of DMB solution were used. A total
of 20mL of water were added to a 96 well plate, as a blank. The
plates were incubated for 10min and then the optical density
was measured in a microplate reader (Bio-Tek, model Synergie
HT), at 525 nm.2.8. Total RNA Isolation
Specimens were gathered at every time point (three per time
point and per cell type), washed in PBS, immersed in TriBiotechnol. J. 2017, 1700073 1700073 (reagent (Sigma, T9424) and kept at 80 C for posterior RNA
extraction. The specimens were taken from the freezer and
thawed for the RNA extraction procedure. Chloroform (Sigma,
C2432) was added; the specimens were vigorously agitated for
15 s and then incubated in ice for 15min. After that incubation,
the specimens were centrifuged at 13 000 rpm, for 15min, at
4 C. Afterwards, the supernatant was collected for a sterile
1.5mL tube, and an equivalent volume of isopropanol (VWR,
437423R) was added. The specimens were incubated at
20 C overnight, to precipitate the RNA. The next day, the
specimens were centrifuged at 13 000 rpm, for 15min, at 4 C.
Then, the supernatant was taken and 800mL of ethanol 70%
was added to wash away the isopropanol. Tubes were agitated
vigorously and centrifuged again, at 9000 rpm for 5min, at 4 C.
The supernatant was again removed, and the pellet was left to
air dry. Finally, the pellet was re-suspended in 20mL of distilled
water DNase, RNase free (Lonza, 733-1631). The concentration
and purity of the extracted RNA was evaluated using the
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technolo-
gies Inc, USA).2.9. Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR)
This procedure consisted of a two-step ﬂuorogenic assay using
the PerfeCtaTM SYBR1 Green system (Quanta Biosciences,
95055-100). All reagents used in this procedure were
purchased from Quanta Biosciences, following the instruc-
tions of the manufacturer. Thermocycler reaction conditions
used performed in accordance to the protocols suggested in
the kit. In the ﬁrst step, RNA was reverse transcribed into
cDNA, using the qScript cDNA Synthesis Kit (95047-500). A
MasterCycler EP Gradient detection system (Eppendorf, USA)
was used to perform the reaction. Afterwards, the obtained
cDNA was used as template for the ampliﬁcation of the target
genes shown in Table 1, with the PerfeCtaTM SYBR1 Green
FastMixTM kit (95072-05K). Tested genes include Aggrecan,
Collagen Type I, Collagen Type II, COMP, and Sox9. GAPDH
was used as house-keeping gene, and the expression of all
target genes was normalized against the GAPDH of the same
specimen for each time point of the study. All primer
sequences were generated using Primer3 software (http://
biotools.umassmed.edu/bioapps/primer3_www.cgi) and ac-
quired from MWG Biotech AG, Germany. Table 1 shows the
details of the primers used.2.10. Morphological Observation of the Constructs
For SEM analysis, samples were collected at 7 and 28 days of
experiment. They were washed in sterile PBS and immersed in
3% glutaraldehyde (Sigma/G-5882) at room temperature for 1 h.
Samples were again washed in PBS, dehydrated in increasing
ethanol concentrations and let to dry. Samples were sputter
coated with gold and analyzed. A scanning electron microscope
(JSM-6010LV, JEOL, Japan) was used to observe cells distribution
and morphologies.© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim3 of 9)










GAPDH AGCCTCAAGATCATCAGCAA 56.3 101 NM_002046.4
GTCATGAGTCCTTCCACGAT
ACAN TGAGTCCTCAAGCCTCCTGT 58.3 129 NM_013227.3
TGGTCTGCAGCAGTTGATTC
COMP AGGGATGGAGACGGACATCAG 58.0 340 NG_007070.1
TCTGCATCAAAGTCGTCCTG
COL Iα AAGAACCCCAAGGACAAGAG 58.4 159 NM_000088.3
GTAGGTGATGTTCTGGGAGG
COL IIα GTTCACGTACACTGCCCTGA 59.4 156 NM_001844.4
TCCACACCGAATTCCTGCTC
SOX9 TTCATGAAGATGACCGACGC 57.9 311 NM_000346.3
GTCCAGTCGTAGCCCTTGAG
www.advancedsciencenews.com www.biotechnology-journal.com2.11. Histological Analysis
Samples were collected at the end of the experiment, ﬁxed in
10% neutral buffered formalin and then kept at 4 C until the
staining procedures. For Alcian Blue staining, samples were
rinse in 3% acetic acid and kept in 1% alcian blue solution
(Sigma A-3157) for 1 h. After that, stain was dispensed and
sections were washed with water, let to dry and then rinsed in
absolute alcohol, cleared in xylene and mounted in Entellan
rapid (VWR, 1.07960.0500).2.12. Immunolocalization of Collagen Type II
Immunolocalization of collagen type II was performed in ﬁxed
samples. Constructs were permeabilized with 0.2% Triton X100Figure 1. Box plots of cells viability and proliferation along the 28 days of the e
U-test.  Denotes significant differences compared to hACs cultures. A) Alama
concentration [μgmL1]) in hACs and hWJSCs.
Biotechnol. J. 2017, 1700073 1700073 ((Sigma, X100) in PBS for 5min and then it was blocked with a
solution of 3% BSA (Sigma, A2153) in PBS for 30min.
Endogenous peroxidase activity was quenched with 0.3%
hydrogen peroxide solution during 30min. Samples were rinsed
in PBS during 5min. R.T.U. Vectastain1Universal Elite ABC Kit
(Vector/VCPK-7200) was used for antibody incubation, according
to the instructions of the manufacturer. Shortly, samples were
incubated with anti-human collagen type II (Millipore Iberica/
MAB1330) overnight at 4 C, in a humidiﬁed atmosphere.
Incubation was revealed by using the Peroxidase Substrate Kit
DAB (Vector/VCSK-4100), according to the instructions of the
manufacturer. Samples were washed in water during 5min and
counterstained with hematoxilin for nuclei visualization. Finally,
slides were mounted in Entellan rapid.2.13. Statistical Analysis
Data were statistically analyzed using IBM SPSS software
(version 21; SPSS Inc.). The Shapiro–Wilk test was ﬁrstly applied
to test the assumption of normality and the results showed that
the data was not following a normal distribution. p values lower
than 0.05 were considered statistically signiﬁcant.3. Results
3.1. Cells Viability and Proliferation
Cell viability and proliferation was assessed during the all
experiment (Figure 1A and B, respectively). HACs showed a
signiﬁcantly higher cell viability than hWJSCs in almost all time
points of the experiment, except for the 21st day, where no
signiﬁcant difference between hACs and hWJSCs was found
(Mann–WhitneyU test, p< 0.005) (Figure 1A). Cell proliferation
results showed no signiﬁcant differences between hACs and
hWJSCs for almost all the time points of the experiment, exceptxperiment. Data were analyzed by nonparametric way of a Mann–Whitney
r blue test results for hACs and hWJSCs. B) Cell proliferation results (DNA
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim4 of 9)
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higher cell proliferation values compared to hACs (Mann–
Whitney U test, p< 0.005), as stated in Figure 1B.3.2. GAGs Accumulation and Expression of
Cartilage-Related Genes
The GAGs content for each type of culture was assessed.
Samples were collected at 7 and 28 days of the experimentFigure 2. Bar plot of chondrogenic markers present in hACs and hWJSCs cu
culture. Data were analyzed by nonparametric way of a Mann–Whitney U-test
plot of the GAGs concentration (μgmL1) in hACs and hWJSCs after 7 and
Whitney U-test.  Denotes significant differences compared to hACs culture
Biotechnol. J. 2017, 1700073 1700073 ((Figure 2, insert). No signiﬁcant difference between hACs and
hWJSCs was found at 28 days of culture, but hWJSCs displayed a
signiﬁcantly higher GAGs concentration than hACs at 7 days of
culture (Mann–Whitney U test, p< 0.05). Accordingly, several
cartilage-related genes expression was also analyzed, and
differences between the expressions in both types of cultures,
on both time points (Figure 2) were determined. Cartilage-
related genes expression sustained the results obtained for
GAGs accumulation in hWJSCs cultures, as Aggrecan, Collagen
type II, and COMP expression was signiﬁcantly higher inltures, normalized for the reference gene GAPDH, after 7 and 28 days of
.  Denotes significant differences compared to hACs cultures. Insert: Box
28 days of culture. Data were analyzed by nonparametric way of a Mann–
s.
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I expression showed a signiﬁcant decrease in those cultures
when compared to hACs. In terms of COMP, hWJSCs displayed
a signiﬁcantly higher expression than hACs at 7 and 28 days.
Aggrecan expression was signiﬁcantly higher at 7 days between
hWJSCs and hACs, but not at 28 days (p¼ 0.067) of experiment.
SOX9 expression was not signiﬁcantly different (p¼ 0.164 at
7 days and p¼ 0.400 at 28 days). No statistical differences were
found for Collagen type II expression at 7 days of culture
(p¼ 0.057), but at 28 days hWJSCs showed signiﬁcantly higher
values of this gene when compared to hACs (p¼ 0.042). Finally,
concerning Collagen type I, no statistically signiﬁcant expression
was found for 7 days of culture (p¼ 0.057), but at 28 days
hWJSCs showed signiﬁcantly lower values when compared to
hACs.3.3. Cells Distribution and Morphology
Both types of cultures were analyzed by SEM to compare their
morphology and distribution at the surface of the NFMs
(Figure 3). Cells showed an even spreading along the PCL
electrospun NFMs. Nevertheless, hACs seemed more dis-
persed than hWJSCs, which were clumped together. Con-
cerning cells morphology, we can observe the typical
chondrocyte round shape either for hACs (Figure 3A and
insert) and hWJSCs, at 7 days of culture (Figure 3B and insert).
There seems to be a loss of the chondrocyte phenotype at the
end of the experiment for hACs (Figure 3C and insert),
whereas for hWJSCs the morphology is maintained
(Figure 3D and insert).Figure 3. Scanning electron micrographs showing the hACs and hWJSCs dis
experiment. Red dots show the round-shaped morphology of hACs.
Biotechnol. J. 2017, 1700073 1700073 (3.4. Histological Results
Alcian blue staining was performed in 28 days samples to
identify sulfated proteoglycans present in cartilage matrix
(Figure 4A–D), conﬁrming the SEM observations. Staining in
the NFMs seeded with hACs was spread along the NFMs, in the
places cells were cultured. In the NFMs seeded with WJSCs,
staining was localized in only one spot, where cells aggregated
and formed cartilage-like ECM. Staining was more intense and
localized, showing the proteoglycans production and
accumulation.
Immunolocalization of collagen type II was also assessed as
this protein is one of the major components of articular cartilage
ECM (Figure 4E–H). Consistent with GAGs quantiﬁcation and
expression of cartilage-related genes, the histological analysis of
hACs and hWJSCs cultures revealed sulfated proteoglycans
deposition on both types of cultures (Figure 4A–D), as well as the
existence of collagen type II in the engineered tissue formed
(Figure 4E–H).4. Discussion
Herein, we demonstrated the ability of hWJSCs chondrogenic
differentiation when seeded onto electrospun PCL NFMswithout
growth factor induction. We have previously shown that PCL
NFMs are suitable for cartilage TE approaches by supporting the
growth, proliferation, and cartilagineous ECM deposition by
bovine articular chondrocytes, either in static or in stirred
conditions.[31] Furthermore, electrospun PCL NFMs also support
and promote human MSCs chondrogenic differentiation when
using a ﬂow perfusion bioreactor for their culture.[34] Importantly,tribution and morphology on the NFMs, at 7 (A, B) and 28 (C, D) days of
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim6 of 9)
Figure 4. Histological analysis of hACs and hWJSCs cultures in PCL nanofiber meshes, at 28 days of culture. A–D) alcian blue staining. E–H) collagen
type II immunolocalization.
www.advancedsciencenews.com www.biotechnology-journal.comwe showed that PCL NFMs support the culture of both normal
bovine chondrocytes,[31] as well as human chondrocytes isolated
from diseased joints. The maintenance of diseased hACs
phenotype when seeded onto the NFMs is one fundamental
aspect in our strategy. Although chondrocytes were isolated from
the cartilage regions not directly affected, they were exposed to the
synovialﬂuid affected by the pathological cartilage. It is speculated
that electrospunPCLNMFswill be used for the treatment ofmain
injuries of cartilage that can, in a further stage, develop into OA.
Therefore, the use of these chondrocytes is important because weBiotechnol. J. 2017, 1700073 1700073 (are testing the cells phenotype present at the implant site, as
representative of a MACI technique with autologous cells.
Obtained results for cell viability and proliferation showed
that hACs, although being signiﬁcantly more metabolically
active than hWJSCs (Figure 1A), have a proliferation rate
signiﬁcantly slower than hWJSCs (Figure 1B). Proliferation
results conﬁrm the enhanced proliferation rate of WJSCs
reported in literature.[19] Human ACs were able to produce
GAGs when seeded onto the electrospun PCL NFMs, along the
experiment (Figure 2, insert). Surprisingly, hWJSCs cultured in© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim7 of 9)
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tiation, presented a signiﬁcantly higher value for GAGs
production, when compared to hACs. Moreover, stem cells
presented signiﬁcantly higher expression of Aggrecan, COMP,
and Collagen type II when equated with hACs (Figure 2).
Moreover, the lower expression of Collagen Type I shows that the
cartilage-like tissue formed is not ﬁbrocartilage. This low
expression indicated that the obtained ECM resembles the
natural articular cartilage. These results are in accordance with
the GAGs production, and show that hWJSCs could be driven in
to the chondrogenic lineage by culturing in electrospun PCL
NFMs using only basal media without any growth factors
induction. One of the critical properties that can control cell in
growth, proliferation within the scaffolds and integration with
the surrounding tissues is the thee-dimensional porous
structure of scaffolds.[37] The pore structure also contributes
to provide cells with the proper nutritional supply and spatial
organization for tissue regeneration,[38] as well as for cells
phenotype development and stability in vitro.[39] Both the
proliferation and differentiation of MSCs can be positively
inﬂuenced by the culture in 3D scaffolds.[40] Moreover, that the
material topography controls cell relations with materials, which
determines their attachment, distribution, and cellular pheno-
type.[41] It was demonstrated in the literature that MSCs can be
attracted into a cartilage defect by the direction of a collagenous
matrix, after drilling a channel in the cartilage structure down to
the subchondral bone.[42] Therefore, we believe that the unique
structure of the electrospun PCL NFMs[28,43] may be providing
cues for triggering stem cells differentiation. Indeed, we could
observe by SEM that hACs could not maintain their typical
round-shape morphology along the 28 days of culture, although
the hWJSCs show this morphology already at the 7th day of
culture (Figure 3). Moreover, these observations are sustained by
the presence of sulfated proteoglycans on both types of cultures
(Figure 4A–D) and also of collagen type II in both chondrocytes
(Figure 4E and G) and hWJSCs (Figure 4F and H). Our results
are in agreement with other reports,[44] that have shown how the
nanoﬁbers architecture can control hBMSC fate. hBMSCs
culture in nanoﬁbers induced osteogenic differentiation without
using osteogenic supplements, suggesting that the scaffold
structure can be designed to guide cells into morphologies that
direct their differentiation toward a chosen lineage.[44] Moreover,
a recent report has described that biochemical (growth factors
supplementation) and physical (nanoﬁber) cues regulated
similar ontological pathways, suggesting an overlap in the
molecular mechanisms that these stimuli use to control stem
cell function.[45] It has also been demonstrated that the structural
properties of the extracellular or cell neighboring microenviron-
ment regulate cell processes and signaling pathways.[39,40,45,46]
Human WJSCs have not been extensively explored for TE
applications when compared to BMSCs, but present several
competitive advantages, namely: 1) a higher frequency of colony
forming units (CFUs-F), allowing obtaining a larger number of
MSCs in the initial isolation procedure[17]; 2) a higher proliferative
potential[19]; 3)WJSCs represent an transitional stem cell type that
partly combines some pluripotent properties of adult MSCs[47]; 4)
extra-embryonic tissue-derived MSCs (such as WJSCs) have
adjacent ontogenetic relationship with embryonic stem cells,
which grants them immune privileged characteristics, and aBiotechnol. J. 2017, 1700073 1700073 (broader multipotent plasticity[48]; 5) WJSCs can be used without
major ethical problems as extra-embryonic tissues are normally
rejected after birth[47,49]; 6) umbilical cords are easy to harvest and
available in largenumbers[19] thus, they aregoodcandidates for the
autologous or allogeneic treatment of several diseases.[50]
Nevertheless, WJSCs are an allogeneic source when compared
to hBMSCs, but their hypoimmunogenicity has been reported,[51]
and it has been shown that hWJSCs express crucial immunomod-
ulatory molecules even when exposed to chondrogenic, osteo-
genic, or adipogenic differentiation in vitro.[52]
Results obtained herein allow us to conclude that we could
beneﬁt from the nanoﬁbrous architecture of our electrospun
NFMs and produce cartilage-like tissue without the addition of
growth factors. Those observations represent an important
progress beyond the available chondrocyte-based strategies
using autologous fetal stem cells regeneration of focal cartilage
lesions. By combining both electrospun NFMs structure and
hWJSCs commitment, we can deﬁne a long term strategy for the
use of these meshes in autologous transplantation approaches,
as they will improve the intrinsic repair activity of focal cartilage
lesions and the surrounding osteoarthritic tissue.Abbreviations
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